Hi,
moomoo ID:NaN
Log Out
English
Back
Download
Log in to access Online Inquiry
Quotes
Detailed Quotes
Company Overview
Company ProfileCompany Executives
Financial Analysis
Main CompositionKey IndicatorsFinancial Statement
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > ALVOW ALVOTECH C/WTS (TO PUR COM) > Detailed Quotes

ALVOW ALVOTECH C/WTS (TO PUR COM)

Watchlist
1.430
-0.070-4.67%
Trading Session  01/31 11:36 ET
High
1.430
Open
1.410
Turnover
2.14K
Low
1.410
Pre Close
1.500
Volume
1.50K
Market Cap
0
P/E(TTM)
0.00
52wk High
1.980
Shares
0
P/E(Static)
0.00
52wk Low
0.360
Float Cap
0
Bid/Ask %
-33.33%
Historical High
1.980
Shs Float
0
Volume Ratio
0.11
Historical Low
0.360
Dividend TTM
--
Div Yield TTM
--
P/B
0.00
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.00%
Amplitude
1.33%
Avg Price
1.423
Lot Size
1
Float Cap
0
Bid/Ask %
-33.33%
Historical High
1.980
Shs Float
0
Volume Ratio
0.11
Historical Low
0.360
Dividend TTM
--
P/B
0.00
Dividend LFY
--
Turnover Ratio
0.00%
Amplitude
1.33%
Avg Price
1.423
Lot Size
1
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast

News

Comment

News

Announcement

No More
Company Overview More
Alvotech (formerly Oaktree Acquisition Corp. II) is a biotech company, founded by Robert Wessman.Alvotech are 800 professionals across multiple countries,focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer.
CEO： Mr. Mark Levick
Market： NASDAQ
Listing Date： 09/17/2020
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Get Started
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist